留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

大肝癌的消融治疗

曹飞 范卫君

曹飞, 范卫君. 大肝癌的消融治疗[J]. 临床肝胆病杂志, 2021, 37(3): 501-505. DOI: 10.3969/j.issn.1001-5256.2021.03.002
引用本文: 曹飞, 范卫君. 大肝癌的消融治疗[J]. 临床肝胆病杂志, 2021, 37(3): 501-505. DOI: 10.3969/j.issn.1001-5256.2021.03.002
CAO F, FAN WJ. Ablation therapy for large hepatocellular carcinoma[J]. J Clin Hepatol, 2021, 37(3): 501-505. DOI: 10.3969/j.issn.1001-5256.2021.03.002
Citation: CAO F, FAN WJ. Ablation therapy for large hepatocellular carcinoma[J]. J Clin Hepatol, 2021, 37(3): 501-505. DOI: 10.3969/j.issn.1001-5256.2021.03.002

大肝癌的消融治疗

DOI: 10.3969/j.issn.1001-5256.2021.03.002
基金项目: 

国家自然科学基金面上项目 81771954

详细信息
    作者简介:

    曹飞(1990—),男,博士,主要从事肿瘤的介入治疗研究

    通讯作者:

    范卫君,fanwj@sysucc.org.cn

  • 利益冲突声明:所有作者均声明不存在利益冲突。
  • 作者贡献声明:曹飞负责文献检索、撰写及修改论文; 范卫君负责拟定写作思路,指导撰写文章并最后定稿。
  • 中图分类号: R735.7

Ablation therapy for large hepatocellular carcinoma

  • 摘要: 肝癌是我国最常见的恶性肿瘤之一,当单个肿瘤直径大于5 cm时定义为大肝癌。大肝癌具有肿瘤恶性程度高、易出现肿瘤转移和血管浸润等特点,增加了治疗的难度。外科切除是大肝癌首选的治疗方案,但仅有20%~30%的患者符合手术治疗要求。对于不可切除的大肝癌国内外指南推荐经肝动脉化疗栓塞术(TACE)作为治疗方案,TACE可以控制肿瘤进展并延长患者生存时间,但反复多次的TACE治疗疗效有限,且对患者肝功能造成严重损害,单独的TACE治疗已无法满足临床需求。随着肿瘤消融技术如射频、微波和冷冻消融等不断发展,TACE联合肿瘤消融治疗已成为大肝癌治疗中的一个重要治疗手段。然而目前国内外关于大肝癌消融治疗的疗效仍有较多的争议,因此如何选择合适的消融时机,减少消融术后残留,降低消融术后肿瘤的复发,最终使患者生存获益是目前临床和科研仍需继续探讨的难题。针对以上内容,综述并分析了大肝癌消融治疗的现况、困境及未来发展趋势。
  • [1] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492
    [2] Bureau of Medical Administration, National Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2020.05.009

    中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.05.009
    [3] FORNER A, REIG M, BRUIX J. Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127): 1301-1314. DOI: 10.1016/S0140-6736(18)30010-2
    [4] LIM C, MISE Y, SAKAMOTO Y, et al. Above 5 cm, size does not matter anymore in patients with hepatocellular carcinoma[J]. World J Surg, 2014, 38(11): 2910-2918. DOI: 10.1007/s00268-014-2704-y
    [5] USTA S, KAYAALP C. Tumor diameter for hepatocellular carcinoma: Why should size matter?[J]. J Gastrointest Cancer, 2020, 51(4): 1114-1117. DOI: 10.1007/s12029-020-00483-z
    [6] LLOVET JM, REAL MI, MONTAÑA X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial[J]. Lancet, 2002, 359(9319): 1734-1739. DOI: 10.1016/S0140-6736(02)08649-X
    [7] LLOVET JM, BRUIX J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival[J]. Hepatology, 2003, 37(2): 429-442. DOI: 10.1053/jhep.2003.50047
    [8] MELCHIORRE F, PATELLA F, PESCATORI L, et al. DEB-TACE: A standard review[J]. Future Oncol, 2018, 14(28): 2969-2984. DOI: 10.2217/fon-2018-0136
    [9] LENCIONI R, de BAERE T, SOULEN MC, et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data[J]. Hepatology, 2016, 64(1): 106-116. DOI: 10.1002/hep.28453
    [10] YOON HM, KIM JH, KIM EJ, et al. Modified cisplatin-based transcatheter arterial chemoembolization for large hepatocellular carcinoma: Multivariate analysis of predictive factors for tumor response and survival in a 163-patient cohort[J]. J Vasc Interv Radiol, 2013, 24(11): 1639-1646. DOI: 10.1016/j.jvir.2013.06.017
    [11] JEONG SO, KIM EB, JEONG SW, et al. Predictive factors for complete response and recurrence after transarterial chemoembolization in hepatocellular carcinoma[J]. Gut Liver, 2017, 11(3): 409-416. DOI: 10.5009/gnl16001
    [12] XUE T, LE F, CHEN R, et al. Transarterial chemoembolization for huge hepatocellular carcinoma with diameter over ten centimeters: A large cohort study[J]. Med Oncol, 2015, 32(3): 64. DOI: 10.1007/s12032-015-0504-3
    [13] TAKAKI H, YAMAKADO K, URAKI J, et al. Radiofrequency ablation combined with chemoembolization for the treatment of hepatocellular carcinomas larger than 5 cm[J]. J Vasc Interv Radiol, 2009, 20(2): 217-224. DOI: 10.1016/j.jvir.2008.10.019
    [14] PENG ZW, ZHANG YJ, CHEN MS, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: A prospective randomized trial[J]. J Clin Oncol, 2013, 31(4): 426-432. DOI: 10.1200/JCO.2012.42.9936
    [15] HU H, CHEN GF, YUAN W, et al. Microwave ablation with chemoembolization for large hepatocellular carcinoma in patients with cirrhosis[J]. Int J Hyperthermia, 2018, 34(8): 1351-1358. DOI: 10.1080/02656736.2018.1462536
    [16] GIORGIO A, GATTI P, MONTESARCHIO L, et al. Microwave ablation in intermediate hepatocellular carcinoma in cirrhosis: An Italian multicenter prospective study[J]. J Clin Transl Hepatol, 2018, 6(3): 251-257. http://www.ncbi.nlm.nih.gov/pubmed/30271736
    [17] HUANG Z, ZUO M, NI J, et al. Assessment in the survival outcome after transarterial chemoembolization combined withcryoablation for hepatocellular carcinoma (diameter > 4 cm) based on the albumin-bilirubingrade and platelet-albumin-bilirubin grade: A preliminary study[J]. Cancer Manag Res, 2020, 12: 1373-1385. DOI: 10.2147/CMAR.S234116
    [18] WEI J, CUI W, FAN W, et al. Unresectable hepatocellular carcinoma: Transcatheter arterial chemoembolization combined with microwave ablation vs. combined with cryoablation[J]. Front Oncol, 2020, 10: 1285. DOI: 10.3389/fonc.2020.01285
    [19] ZHU C, LIN S, LIANG J, et al. PD-1 blockade enhances the anti-tumor immune response induced by cryoablation in a murine model of renal cell carcinoma[J]. Cryobiology, 2019, 87: 86-90. DOI: 10.1016/j.cryobiol.2019.01.015
    [20] ROSS AE, HURLEY PJ, TRAN PT, et al. A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer[J]. Prostate Cancer Prostatic Dis, 2020, 23(1): 184-193. DOI: 10.1038/s41391-019-0176-8
    [21] ZHANG TQ, HUANG ZM, SHEN JX, et al. Safety and effectiveness of multi-antenna microwave ablation-oriented combined therapy for large hepatocellular carcinoma[J]. Therap Adv Gastroenterol, 2019, 12: 1756284819862966. http://www.ncbi.nlm.nih.gov/pubmed/31489030
    [22] TOSO C, MENTHA G, KNETEMAN NM, et al. The place of downstaging for hepatocellular carcinoma[J]. J Hepatol, 2010, 52(6): 930-936. DOI: 10.1016/j.jhep.2009.12.032
    [23] SHI F, WU M, LIAN SS, et al. Radiofrequency ablation following downstaging of hepatocellular carcinoma by using transarterial chemoembolization: Long-term outcomes[J]. Radiology, 2019, 293(3): 707-715. DOI: 10.1148/radiol.2019181991
    [24] SHI F, LIAN S, MAI Q, et al. Microwave ablation after downstaging of hepatocellular carcinoma: Outcome was similar to tumor within Milan criteria[J]. Eur Radiol, 2020, 30(5): 2454-2462. DOI: 10.1007/s00330-019-06604-y
    [25] REN H, AN C, LIANG P, et al. Ultrasound-guided percutaneous microwave ablation assisted by athree-dimensional visualization treatment platform combined with transcatheter arterial chemoembolization for a single large hepatocellular carcinoma 5 cm or larger: A preliminary clinical application[J]. Int J Hyperthermia, 2019, 36(1): 44-54. DOI: 10.1080/02656736.2018.1530459
    [26] SCHULLIAN P, JOHNSTON EW, PUTZER D, et al. Safety and efficacy of stereotactic radiofrequency ablation for very large (≥8 cm) primary and metastatic liver tumors[J]. Sci Rep, 2020, 10(1): 1618. DOI: 10.1038/s41598-020-58383-y
    [27] LLOVET JM, RICCI S, MAZZAFERRO V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med. 2008, 359(4): 378-390. DOI: 10.1056/NEJMoa0708857
    [28] DHANASEKARAN R, NAULT JC, ROBERTS LR, et al. Genomic medicine and implications for hepatocellular carcinoma prevention and therapy[J]. Gastroenterology, 2019, 156(2): 492-509. DOI: 10.1053/j.gastro.2018.11.001
    [29] CHEN S, CAO Q, WEN W, et al. Targeted therapy for hepatocellular carcinoma: Challenges and opportunities[J]. Cancer Lett, 2019, 460: 1-9. DOI: 10.1016/j.canlet.2019.114428
    [30] ZHU K, HUANG J, LAI L, et al. Medium or large hepatocellular carcinoma: Sorafenib combined with transarterial chemoembolization and radiofrequency ablation[J]. Radiology, 2018, 288(1): 300-307. DOI: 10.1148/radiol.2018172028
    [31] EL-KHOUEIRY AB, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502. DOI: 10.1016/S0140-6736(17)31046-2
    [32] ZHU AX, FINN RS, EDELINE J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial[J]. Lancet Oncol, 2018, 19(7): 940-952. DOI: 10.1016/S1470-2045(18)30351-6
    [33] FINN RS, QIN S, IKEDA M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905. DOI: 10.1056/NEJMoa1915745
    [34] CHU KF, DUPUY DE. Thermal ablation of tumours: Biological mechanisms and advances in therapy[J]. Nat Rev Cancer, 2014, 14(3): 199-208. DOI: 10.1038/nrc3672
    [35] SHI L, CHEN L, WU C, et al. PD-1 Blockade boosts radiofrequency ablation-elicited adaptive immune responses against tumor[J]. Clin Cancer Res, 2016, 22(5): 1173-1184. DOI: 10.1158/1078-0432.CCR-15-1352
    [36] NOUSO K, MIYAHARA K, UCHIDA D, et al. Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan[J]. Br J Cancer, 2013, 109(7): 1904-1907. DOI: 10.1038/bjc.2013.542
    [37] BURKI TK. Hepatic arterial chemotherapy for hepatocellular carcinoma[J]. Lancet Oncol, 2019, 20(6): e301. DOI: 10.1016/S1470-2045(19)30343-2
    [38] LYU N, LIN Y, KONG Y, et al. FOXAI: A phase Ⅱ trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma[J]. Gut, 2018, 67(2): 395-396. http://www.ncbi.nlm.nih.gov/pubmed/28592441
    [39] HE M, LI Q, ZOU R, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: A randomized clinical trial[J]. JAMA Oncol, 2019, 5(7): 953-960. DOI: 10.1001/jamaoncol.2019.0250
    [40] GOTO Y, HISAKA T, SAKAI H, et al. Salvage surgery for initially unresectable locally advanced hepatocellular carcinoma downstaged by hepatic arterial infusion chemotherapy[J]. Anticancer Res, 2020, 40(8): 4773-4777. DOI: 10.21873/anticanres.14479
  • 加载中
计量
  • 文章访问数:  98
  • HTML全文浏览量:  22
  • PDF下载量:  37
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-12-30
  • 修回日期:  2021-01-10
  • 刊出日期:  2021-03-16
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回